AIDS 2022 spotlights a game-changing tool to prevent sexually transmitted infections and key advances in HIV cure research

27 July 2022 (Montreal, Canada) – New studies presented at AIDS 2022, the 24th International AIDS Conference, hosted by IAS – the International AIDS Society – demonstrate promising advances in the global HIV response.

Speaking at a virtual press conference, authors shared:

• Successful results from a trial of the antibiotic doxycycline to prevent sexually transmitted infections (STIs)
• Reports of two adults in long-term remission off antiretroviral therapy (ART)
• A new method using microfluidics to define a biomarker of the HIV reservoir
• News of Botswana surpassing global 95-95-95 targets to nearly eradicate the epidemic in the country
• Promising results of a triple-therapy regimen for people living with both HIV and hepatitis B

“A cure remains the Holy Grail of HIV research,” Sharon Lewin, IAS President-Elect and Director of The Peter Doherty Institute for Infection and Immunity, said. “We have seen a handful of individual cure cases before, and the two presented today provide continued hope for people living with HIV and inspiration for the scientific community. What’s more, we are now seeing an advance in the great challenge of finding a biomarker for the HIV reservoir – a truly exciting development.”

Today’s scientific press conference highlighted six studies selected from thousands of abstracts being presented over the next week in Montreal and virtually.

Read the full announcement here.

SEE ALSO:

• Medical Xpress: Botswana hits ‘historic’ UN goal against HIV: report